---
title: "\"Performance\" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280339120.md"
description: "LIVZON PHARMA announced its 2025 annual performance, achieving operating revenue of 12.02 billion RMB (same below), an increase of 1.8% year-on-year. The net profit attributable to shareholders was 2.023 billion RMB, a decline of 1.8%, with earnings per share of 2.24 RMB. A dividend of 14.3 RMB per 10 shares was declared"
datetime: "2026-03-24T15:01:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280339120.md)
  - [en](https://longbridge.com/en/news/280339120.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280339120.md)
---

# "Performance" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 shares

LIVZON PHARMA (01513.HK) announced its performance for the fiscal year 2025, achieving operating revenue of 12.02 billion RMB (same below), an increase of 1.8% year-on-year. The net profit attributable to shareholders was 2.023 billion RMB, a decline of 1.8%, with earnings per share of 2.24 RMB. A dividend of 14.3 RMB will be distributed for every 10 shares

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [512170.CN](https://longbridge.com/en/quote/512170.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)